Clinical Trial Update: A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating SHR6390 in combination with Fulvestrant for HR-positive, HER2-negative advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• SHR6390 (SHR6390)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Advanced Breast Cancer | Phase 3 | Status: UNKNOWN